GlassScriptPhysician profile
David M Arnopole
NPI 1720647225
$38,264.48
in general payments reported to CMS, 2019-2025
68 companies · $15K in 2025
The $15K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $5,487 · 2023: $8,038 · 2024: $9,572 · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $23K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,813 · Travel and Lodging: $3,486 · Education: $453.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $23,025.28 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,812.50 |
| Travel and Lodging | $3,486.13 |
| Education | $453.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tg Therapeutics, INC. | $9,286.37 | 2023-2025 | |
| Biogen, INC. | $2,826.08 | 2022-2025 | Vumerity, Tysabri, Tysabri |
| Abbvie INC. | $2,792.59 | 2022-2025 | |
| Emd Serono, INC. | $2,345.97 | 2022-2025 | Mavenclad, Mavenclad |
| Ucb, INC. | $1,272.81 | 2022-2025 | Rystiggo, Briviact, Zilbrysq |
| Livanova USA, INC. | $1,154.76 | 2022-2025 | Vns Therapy, Vns Therapy Sentiva Model 1000 Generator |
| Alexion Pharmaceuticals, INC. | $1,140.25 | 2022-2025 | Ultomiris |
| Eisai INC. | $1,105.11 | 2022-2025 | |
| Merz Pharmaceuticals, LLC | $988.17 | 2022-2025 | Xeomin, Inbrija, Ampyra |
| Novartis Pharmaceuticals Corporation | $976.63 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $964.47 | 2022-2025 | Austedo Xr, Austedo Xr, Austedo |
| Argenx US, INC. | $926.00 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Pfizer INC. | $793.35 | 2023-2025 | |
| Medtronic, INC. | $789.72 | 2023-2025 | Percept PC Brainsense, Intellis Adaptivestim, Ascenda |
| Nevro Corp. | $701.00 | 2023-2024 | Senza |
Show all 68 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $694.30 | 2022-2025 | Nuplazid |
| Lundbeck LLC | $667.69 | 2023-2025 | Vyepti, Rexulti |
| Neurocrine Biosciences, INC. | $558.79 | 2022-2025 | Ingrezza, Ongentys |
| Genentech USA, INC. | $534.54 | 2022-2025 | Ocrevus, Enspryng, Ocrevus Zunovo |
| Catalyst Pharmaceuticals, INC. | $448.93 | 2023-2025 | Fycompa |
| Impel Pharmaceuticals INC. | $445.15 | 2022-2023 | Trudhesa |
| Neurelis, INC. | $441.59 | 2022-2025 | Valtoco |
| Sk Life Science, INC. | $440.77 | 2022-2025 | Xcopri |
| Biohaven Pharmaceutical Holding Company LTD. | $431.20 | 2022 | |
| Jazz Pharmaceuticals INC. | $413.45 | 2022-2024 | |
| Otsuka America Pharmaceutical, INC. | $412.91 | 2023-2025 | Rexulti, Nuedexta |
| Genzyme Corporation | $386.89 | 2022-2025 | |
| Alnylam Pharmaceuticals INC. | $325.62 | 2023-2025 | Amvuttra, Onpattro |
| Lilly USA, LLC | $309.97 | 2022-2025 | Kisunla, Emgality, Reyvow |
| Abbott Laboratories | $254.92 | 2023-2025 | Infinity |
| Boston Scientific Corporation | $241.89 | 2024-2025 | General - Dbs |
| Janssen Biotech, INC. | $237.89 | 2025 | |
| Genentech, INC. | $189.78 | 2022-2024 | Ocrevus |
| Mdd US Operations, LLC | $184.73 | 2022-2025 | Gocovri |
| Kyowa Kirin, INC. | $173.54 | 2022-2024 | Nourianz |
| Amgen INC. | $170.01 | 2024-2025 | Uplizna |
| Scilex Pharmaceuticals INC. | $165.43 | 2023-2025 | Ztlido |
| Vanda Pharmaceuticals INC. | $157.93 | 2024-2025 | Ponvory |
| Ipsen Biopharmaceuticals, INC | $152.10 | 2022-2025 | Dysport |
| Banner Life Sciences, LLC | $138.41 | 2022-2024 | |
| Silk Road Medical, INC. | $135.37 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter, Enroute Transcarotid Stent |
| Acorda Therapeutics, INC | $120.97 | 2022-2024 | Ampyra, Inbrija |
| Astrazeneca Pharmaceuticals LP | $120.00 | 2025 | Wainua |
| Horizon Therapeutics Plc | $114.05 | 2022 | |
| Globus Medical, INC. | $107.29 | 2025 | Senza |
| Amarin Pharma, INC. | $96.20 | 2025 | Vascepa |
| Harmony Biosciences LLC | $95.03 | 2023 | Wakix |
| Octapharma USA, INC. | $86.79 | 2023-2025 | Panzyga |
| Sunovion Pharmaceuticals INC. | $72.22 | 2022 | |
| Sandoz INC. | $65.97 | 2023-2024 | |
| Tanabe Pharma America, INC. | $64.03 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $52.14 | 2022-2024 | Hyqvia |
| Axsome Therapeutics, INC. | $48.52 | 2025 | Symbravo |
| Upsher-Smith Laboratories LLC | $47.84 | 2022-2023 | |
| Grifols USA, LLC | $42.03 | 2025 | Gamunex-C |
| Sumitomo Pharma America, INC. | $41.19 | 2023 | Aptiom |
| Supernus Pharmaceuticals, INC. | $39.69 | 2022 | |
| Janssen Pharmaceuticals, INC | $35.87 | 2022 | |
| Amneal Pharmaceuticals LLC | $33.55 | 2023-2024 | Rytary |
| Mallinckrodt Hospital Products INC. | $30.30 | 2025 | Acthar |
| Ani Pharmaceuticals, INC. | $26.42 | 2023 | Purified Cortrophin Gel |
| Csl Behring | $25.86 | 2022 | |
| Averitas Pharma INC. | $25.62 | 2024 | Qutenza |
| Ge Healthcare | $24.52 | 2025 | |
| Bioventus LLC | $19.53 | 2024 | L300 Go System |
| Cycle Pharmaceuticals INC | $18.46 | 2025 | Tascenso Odt |
| Aucta Pharmaceuticals, INC. | $17.24 | 2025 | Motpoly Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.07 | 2024 | Caplyta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Arnopole listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.